drug
tradipitant
Marketedupdated 3mo agoby $VNDA Vanda Pharmaceuticals Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying tradipitant
- phase3A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- phase3Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
- phase2A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
- —Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis
- phase3Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
- phase2Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
- phase3Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
- phase3Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 30, 2030
~4.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Aug 9, 2036method-of-use (U-4396)US 12318375
- Mar 4, 2036method-of-use (U-4396)US 10772880
- Mar 4, 2036method-of-use (U-4396)US 10821099
- Mar 4, 2036method-of-use (U-4396)US 11324735
FDA exclusivities (1)
- Dec 30, 2030NCENew Chemical Entity (5y)4.4y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that